CTOs on the Move


 
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.amylyx.com
  • 43 Thorndike Street
    Cambridge, MA USA 02141
  • Phone: 617.682.0917

Executives

Name Title Contact Details

Funding

Amylyx raised $14.7M on 01/28/2020

Similar Companies

Stason Pharmaceuticals Inc

Stason Pharmaceuticals Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

Beacon Orthopaedics & Sports Medicine

Beacon Orthopaedics has 40 renowned orthopedic surgeons providing Cincinnati, Dayton, NKY and Indiana specialized sports medicine and orthopedic care.

BioCareSD

BioCareSD is a specialty distributor of biological products for hemophilia, thrombophilia, immunology, critical care, and ALS. They are committed to providing customer-oriented solutions, unmatched service levels, and a unique distribution network to e...

Noven

Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.